| |
|
|
| |
Alfred E. Mann |
|
ALFRED E. MANN, BIOMEDICAL INDUSTRY ENTREPRENEUR, SCIENTIST AND NOTED PHILANTHROPIST TO SPEAK AT CASE
CLEVELAND – Biomedical industry entrepreneur, innovative scientist and noted philanthropist Alfred E. Mann will share his considerable insights on "Engineering for Success" at Case Western Reserve University on Thursday, September 23, at 6 p.m. at the Wolstein Research Building at Cornell and Circle Drive. Mann will be speaking as part of the David B. Deioma Lecture Series, sponsored by the university's Institute for Management and Engineering (TIIME) and the Case School of Engineering.
Mann is chairman of the board of trustees of The Alfred Mann Foundation and the Alfred Mann Institute for Biomedical Engineering at the University of Southern California. He also is chairman and co-CEO of Advanced Bionics Corp., which develops, manufactures and markets systems for neuromuscular electrical stimulation systems, as well as marketing cochlear stimulators to restore hearing for the profoundly deaf.
Mann also is chairman of Second Sight, LLC, an early stage company developing a visual prosthesis to restore sight to the blind; Allecure Corp., which is developing vaccines for eliminating allergies; Quallion, LLC, which manufactures components for use in medical and aerospace products; and chairman emeritus of Pacesetter System, Inc., a worldwide pacemaker manufacturer and distributor, all companies he founded. Mann also is chairman of CTL Immunotherapy Inc., which develops therapeutic vaccines primarily for treating cancer, and Pharmaceutical Discovery Corp., which has developed stabilizing microencapsulation technology that can enable deep pulmonary, nasal and oral delivery of proteins and peptides as well as other drugs.
The Alfred E. Mann Institute for Biomedical Engineering at USC is a nonprofit corporation engaged in biomedical research and development. Its mission is to conduct biomedical research and to foster the development and commercialization of biomedical devices and other biomedical technologies. AMI-USC collaborates with the USC faculty to identify, validate, develop and transition to private industry new concepts for use in promoting public health. Its aim is to move promising new technology from the idea stage to successful commercialization in a short period of time.
Prior to his involvement in the medical device industry, Mann had also been founder and was president of Spectrolab in Sylmar , Calif. , for 16 years. After a vigorous early growth, Spectrolab joined Textron, Inc., and became a world leader in photovoltaic power systems, solar simulation, high intensity (airborne) illumination systems and optical thin films. Before founding Spectrolab, Mann was a group supervisor at Technicolor Corp., where he directed research and development in the fields of instrumentation radiation damage, optical physics, multilayer thin film vacuum deposition and digital and analog computer analysis.
In addition to his business activities, Mann has contributed significantly to numerous technical advances in medical devices, power conversion, illumination, radiometry, thin-film optics and advanced mathematical analysis.
Mann holds bachelors and masters degrees in physics from the University of California at Los Angeles , honorary doctorates from USC, Johns Hopkins University and Western University and is a member of the National Academy of Engineering.
The goal of the Deioma Lectureship is to educate the community in various aspects of technology-based new venture creation and entrepreneurship. This includes such issues as the role of intellectual property, characteristics of the entrepreneur, financing new ventures and many other aspects of starting a high growth company. The lectureship is made possible by a generous gift to the Case School of Engineering from David B. Deioma, an alumnus of the former Case Institute of Technology.
For event and registration information, visit TIIME´s web site at http://www.tiime.case.edu/lecture/index.html or call TIIME at (216) 368-0596.
|
